StreetInsider.com News Articles

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].

According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.

Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Tue, 28 Jul 2026 14:32:00 -0400

ELMWOOD PARK, N.J., July 28, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION^®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
According to IQVIA^® sales data for the 12-month period ending May 2026, the BRIDION^® Injection, 100 mg/mL market³ achieved annual sales of approximately $1.6 billion*.
Commenting

Cosmo and Glenmark Announce Market Authorisation of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 17 countries in Europe

Mon, 01 Dec 2025 09:31:00 -0400

DUBLIN and MUMBAI, India, Dec. 1, 2025 /PRNewswire/ -- Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Glenmark Pharmaceuticals Limited (Glenmark), announced that the European Commission (EC) has granted Marketing Authorization (MA) for Winlevi® (clascoterone 10 mg/g cream), following the positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on August 25, 2025.

Winlevi® is authorized in EU for the

Cosmo and Glenmark Announce Market Authorisation of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 17 countries in Europe

Mon, 01 Dec 2025 09:31:00 -0400

DUBLIN and MUMBAI, India, Dec. 1, 2025 /PRNewswire/ -- Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Glenmark Pharmaceuticals Limited (Glenmark), announced that the European Commission (EC) has granted Marketing Authorization (MA) for Winlevi® (clascoterone 10 mg/g cream), following the positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on August 25, 2025.

Winlevi® is authorized in EU for the

Cosmo and Glenmark Announce Market Authorisation of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 17 countries in Europe

Mon, 01 Dec 2025 09:31:00 -0400

DUBLIN and MUMBAI, India, Dec. 1, 2025 /PRNewswire/ -- Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Glenmark Pharmaceuticals Limited (Glenmark), announced that the European Commission (EC) has granted Marketing Authorization (MA) for Winlevi® (clascoterone 10 mg/g cream), following the positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on August 25, 2025.

Winlevi® is authorized in EU for the